| scholarly article | Q13442814 |
| P2093 | author name string | Yanjun Fu | |
| David M Shames | |||
| Michael F Wendland | |||
| Robert C Brasch | |||
| Clemens C Cyran | |||
| Bundit Chaopathomkul | |||
| Victor Rogut | |||
| P2860 | cites work | Gadolinium MRI contrast agents based on triazine dendrimers: relaxivity and in vivo pharmacokinetics | Q30571992 |
| Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization | Q31049016 | ||
| Cascade polymeric MRI contrast media derived from poly(ethylene glycol) cores: initial syntheses and characterizations | Q31107862 | ||
| Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine | Q32074895 | ||
| Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging | Q33768662 | ||
| Macromolecular and dendrimer-based magnetic resonance contrast agents | Q34069230 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF). | Q35622504 | ||
| Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels | Q36230478 | ||
| Promise and progress for functional and molecular imaging of response to targeted therapies. | Q36769980 | ||
| Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique | Q36784358 | ||
| In pursuit of new anti-angiogenic therapies for cancer treatment | Q37825180 | ||
| Imaging assessment of tumor response: past, present and future | Q37875082 | ||
| Benefit-risk assessment of bevacizumab in the treatment of breast cancer. | Q37963955 | ||
| MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. | Q40165236 | ||
| Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. | Q40540980 | ||
| Assessing tumor angiogenesis using macromolecular MR imaging contrast media. | Q41352765 | ||
| Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. | Q41559635 | ||
| Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers | Q43410555 | ||
| Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization | Q43962639 | ||
| New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. | Q45945812 | ||
| Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations | Q46090532 | ||
| Quantification of tissue gadolinium concentration using magnetic resonance imaging: comparison of ultrashort inversion time inversion recovery echoplanar and dynamic three-dimensional spoiled gradient-recalled approaches with in vitro measurements | Q46319505 | ||
| Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor | Q46319983 | ||
| The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. | Q46423431 | ||
| Perfusion MRI for Monitoring the Effect of Sorafenib on Experimental Prostate Carcinoma: A Validation Study | Q59689546 | ||
| Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents | Q73266332 | ||
| Steady-state and dynamic MR angiography with MS-325: initial experience in humans | Q74521657 | ||
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma | Q83195713 | ||
| FDA pulls approval for avastin in breast cancer | Q84133234 | ||
| P433 | issue | 10 | |
| P921 | main subject | bevacizumab | Q413299 |
| angiogenesis inhibitor | Q574834 | ||
| macromolecule | Q178593 | ||
| P304 | page(s) | 1256-1263 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Academic Radiology | Q15755259 |
| P1476 | title | Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model | |
| P478 | volume | 20 |
| Q26774810 | 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives |
| Q36750627 | Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. |
| Q39246340 | Contrast agents in dynamic contrast-enhanced magnetic resonance imaging |
| Q35867668 | Magnetic resonance-guided regional gene delivery strategy using a tumor stroma-permeable nanocarrier for pancreatic cancer |
Search more.